Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,300 papers from all fields of science
Search
Sign In
Create Free Account
nivolumab
Known as:
NIVO
A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
6 relations
10 ML nivolumab 10 MG/ML Injection [Opdivo]
Monoclonal Antibodies
NCIt Antineoplastic Agent Terminology
antigen binding
Broader (1)
Antineoplastic Agents
Narrower (1)
MDX-1106
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
A phase II study of ipilimumab and nivolumab with radiation in microsatellite stable (MSS) metastatic colorectal adenocarcinoma (mCRC).
A. Parikh
,
Jeffrey W. Clark
,
+15 authors
T. Hong
Journal of Clinical Oncology
2019
Corpus ID: 190893626
3514 Background: mCRC remains a lethal cancer and immunotherapy in MSS mCRC has yet to show significant activity. In preclinical…
Expand
2018
2018
Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors.
R. Sullivan
,
D. Hong
,
+13 authors
J. Wolchok
2018
Corpus ID: 81330885
3013Background: IPI-549 is a potential first-in-class, oral, selective PI3K-γ inhibitor that in preclinical studies reprograms…
Expand
2017
2017
A case of new‐onset antibody‐positive myasthenia gravis in a patient treated with pembrolizumab for melanoma
I. Alnahhas
,
J. Wong
Muscle and Nerve
2017
Corpus ID: 32747759
1. Becker PE. Myotonia congenita and syndromes associated with myotonia: clinical-genetic studies of the nondystrophic myotonias…
Expand
2017
2017
Case of type 1 diabetes associated with less‐dose nivolumab therapy in a melanoma patient
Y. Teramoto
,
Yasuhiro Nakamura
,
+7 authors
A. Yamamoto
Journal of dermatology (Print)
2017
Corpus ID: 22739765
gates of foamy histiocytes in the dermis and verrucous acanthosis. Regarding its pathogenesis, it is thought that the epithelial…
Expand
Review
2017
Review
2017
Recent advances in genitourinary tumors: A review focused on biology and systemic treatment.
A. González del Alba
,
J. Arranz
,
+13 authors
C. Suarez
Critical reviews in oncology/hematology
2017
Corpus ID: 21787926
2016
2016
Nivolumab-induced thyroid dysfunction.
R. Tanaka
,
Y. Fujisawa
,
+4 authors
M. Fujimoto
Japanese Journal of Clinical Oncology
2016
Corpus ID: 22801930
Nivolumab (ONO-4538) is an anti-programmed death-1 specific monoclonal antibody, which has become a standard treatment for…
Expand
Highly Cited
2016
Highly Cited
2016
Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): Results from the CheckMate-032 study.
D. Le
,
J. Bendell
,
+13 authors
Y. Janjigian
2016
Corpus ID: 79157577
6 Background: Patients (pts) with GC/GEC often present with A/M disease, which has a poor prognosis, with 1-year survival < 30…
Expand
2016
2016
Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer (mUC): Results from the phase I/II CheckMate 032 study.
Padmanee Sharma
,
P. Bono
,
+14 authors
J. Rosenberg
2016
Corpus ID: 59227165
4501Background: Minimal antitumor activity of existing therapies and the observation of immune dysfunction in bladder cancer have…
Expand
2016
2016
Perspective: What next for treatment?
R. Motzer
Nature
2016
Corpus ID: 4456177
We need to focus on five main areas to make real progress in the treatment of kidney cancer, says Robert J. Motzer.
Highly Cited
2014
Highly Cited
2014
Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial.
T. Choueiri
,
M. Fishman
,
+17 authors
M. Sznol
2014
Corpus ID: 79440085
5012 Background: Nivolumab, a fully human IgG4 programmed death-1 (PD-1) inhibitor antibody, has shown encouraging activity in…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE